2013 Archived Content
Second Annual

Bioinformatics in the Genome Era

Understanding the Evolving Role of Bioinformatics in Molecular Medicine

 

Day 1 | Day 2 | Day 3 

Thursday, February 14

7:00 am Breakfast Presentation (Sponsorship Opportunity Available) or Morning Coffee





 
8:00 - 9:40 Plenary Keynote Panel: Emerging Technologies & Industry Perspectives 

This session features a series of presentations on emerging and hot technologies in diagnostics, drug discovery & development, informatics, and oncology. Interactive Q&A discussion with the audience will be included. - Read more 

Sponsored by


Biocartis  Elsevier  Luminex  RemedyMD  Scientia Advisors  Singulex 

9:40 Refreshment Break in the Exhibit Hall with Poster Viewing

 

Collaborations: Role of Bioinformatics and its Positive Impact on Translational Medicine 

10:40 Chairperson’s Remarks

10:45 PANEL DISCUSSION: Nationwide Children’s Presents a Multifaceted Computational Approach to Pediatric Care

Moderator: Andrzej Kloczkowski, Ph.D., Professor, Battelle Center for Mathematical Medicine, The Research Institute at Nationwide Children's Hospital and Department of Pediatrics, The Ohio State University College of Medicine

Saras Saraswathi Ph.D., Postdoctoral Research Associate, Battelle Center for Mathematical Medicine, The Research Institute at Nationwide Children’s Hospital

Richard Ransom, Ph.D., Principal Investigator, Center for Clinical and Translational Research and Faculty, Nephrology and Urology Research Affinity Group, The Research Institute at Nationwide Children’s Hospital

Peter Houghton, Ph.D., Principal Investigator, Hematology/Oncology & Blood and Marrow Transplant (BMT) and Director, Center for Childhood Cancer and Blood Diseases, The Research Institute at Nationwide Children’s Hospital

Maqsood Chotani, Ph.D., Principal Investigator, Center for Cardiovascular and Pulmonary Research Heart Center, The Research Institute at Nationwide Children's Hospital

Computational scientists at the Kloczkowski research group, Battelle Center for Mathematical Medicine, have taken the initiative to collaborate with several of the researchers and clinical doctors at The Research Institute (RI) and Nationwide Children’s Hospital (NCH). In the past year, these collaborations with clinical researchers, who conduct studies relating to childhood cancer, nephrotic syndrome, cardiovascular and infectious diseases, have brought synergy and determination to combat childhood diseases. This session will share our experiences and perspectives in applying computational techniques to these studies and working together with scientists coming from widely varying fields of research.

12:15 pm Luncheon Presentations (Sponsorship Opportunities Available) or Lunch on Your Own

1:15 Refreshment Break in the Exhibit Hall with Poster Viewing

 

Implementing the Rapid-Learning Healthcare System for Cancer Care 

1:40 Panel Discussion: Implementing the Rapid-Learning Healthcare System for Cancer Care

This session examines the elements of a rapid-learning system for cancer care, including registries and databases and emerging information technology and bioinformatics tools.

Moderator: Marcia Kean, Chairman, Strategic Initiatives, Feinstein Kean Healthcare

~William S. Dalton, Ph.D., M.D., CEO, M2Gen; Director, Personalized Medicine Institute, Moffitt Cancer Center

~Lewis Frey, Ph.D., Assistant Professor, Biomedical Informatics, University of Utah

~Dietrich A. Stephan, Ph.D., President and CEO, Silicon Valley Biosystems, Inc. 

~Peter Yu, M.D., Medical Oncologist and Hematologist, Palo Alto Medical Foundation; Chair, Health Information Technology Work Group, The American Society of Clinical Oncology; Co-Chair, Oncology Certification Work Group, Commission for the Certification of Health Information Technology

Improver3:15 Translational Systems Biology: Understanding the Limits of Animal Models as Predictors of Human Biology

Kahn Rhrissorrakrai, Ph.D., Post-Doctoral Researcher, Functional Genomics and Systems Biology, IBM Thomas J. Watson Research Center

Inferring how humans may respond to external stimuli is an essential question in biomedicine. This presentation describes a series of ‘competitive crowd sourcing challenges’ within the SBV IMPROVER project sbvimprover.com that address the issue of translatability between humans and rodents.

3:30 Sponsored Presentation (Opportunity Available) 

3:45 Valentine’s Day Celebration and Poster Competition Winner Announced in the Exhibit Hall

(Last Chance to View Posters)

 

Bioinformatics in Translational Medicine: Systems Biology Approaches 

4:30 Chairperson’s Remarks

Manuel C. Peitsch, Ph.D., Vice President, Biological Systems Research, Philip Morris International Research & Development

4:35 FEATURED PRESENTATION: Systems Approaches to Molecular Diagnostics and Perturbed Network Identification

Nathan Price, Ph.D., Associate Professor, Institute for Systems Biology

This presentation discusses broad sources of inter-study variance that can significantly affect reproducibility and accuracy of molecular diagnostics as they move from lab experiment towards the clinic as well as systems appraoches for dealing with these challenges.  Also discussed will be network analysis techniques to better link molecular signiatures with underlying biological mechanisms.  Such integrations are critical to harnessing the tremendous potential of -omics technologies to revolutionize medicine.

5:05 Robust Statistical Approach for Cancer Research

Svetlana Amirova, Ph.D., Assistant Professor, Mathematics, University of Texas at El Paso

We apply a systems biology approach to study genetic aspects of metabolich pathway regulation for cancer research. To demonstrate universality of this approach, we apply this computational framework to work with biological data motivated by cancer research.

5:35 Predicting Drug Response from Cancer Cell Lines

Adam Margolin, Ph.D., Computational Biology, Sage Bionetworks

6:05 Structural Bioinformatics Analysis Predicts Superior Kinome Selectivity of Clinical p38 MAPK Inhibitor

Li Xing, Ph.D., Senior Principal Scientist, Pfizer

PH-797804 is a p38 kinase inhibitor derived from a racemic mixture as the more potent atropisomer. Structural bioinformatics mining of human kinase genome identified a selectivity motif on the kinase hinge. PH-797804 exhibited high specificity against MAPK and large kinase panels, which translated well to cellular systems. Safety was proven in Phase I clinical trials. Efficacy was achieved in certain human disease population.

6:35 Close of Day

 

 

Day 1 | Day 2 | Day 3 




Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag 

 

2015 Brochure cover 

Premier Sponsors:

Abbott Molecular 

 

Elsevier  


Jackson Laboratory - small logo 

Leica Biosystems 
 

 NanoString2   

 

Silicon Biosystems 

 

Singulex 

Thomson Reuters-Large